Livzon Pharmaceutical Group Inc. (1513.HK)
HKD 25.9
(0.39%)
HKD 25.9
(0.39%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.32 Billion CNY | 12.11% |
| 2022 | 3.08 Billion CNY | 14.78% |
| 2021 | 2.77 Billion CNY | -4.03% |
| 2020 | 2.9 Billion CNY | 36.73% |
| 2019 | 2.11 Billion CNY | 18.38% |
| 2018 | 1.36 Billion CNY | -69.26% |
| 2017 | 5.97 Billion CNY | 297.56% |
| 2016 | 1.29 Billion CNY | 19.43% |
| 2015 | 1.15 Billion CNY | 27.21% |
| 2014 | 925.99 Million CNY | 15.96% |
| 2013 | 806.88 Million CNY | 12.37% |
| 2012 | 729.48 Million CNY | 13.11% |
| 2011 | 626.24 Million CNY | 0.77% |
| 2010 | 665.5 Million CNY | 2.61% |
| 2009 | 733.57 Million CNY | 12.63% |
| 2008 | 281.45 Million CNY | -14.73% |
| 2007 | 676.29 Million CNY | 108.74% |
| 2006 | 323.98 Million CNY | 30.88% |
| 2005 | 247.55 Million CNY | 2.33% |
| 2004 | 241.91 Million CNY | -3.73% |
| 2003 | 251.29 Million CNY | 23.12% |
| 2002 | 204.89 Million CNY | 6.27% |
| 2001 | 190.7 Million CNY | 62.21% |
| 2000 | 97.24 Million CNY | 182.17% |
| 1999 | 38.87 Million CNY | -6.3% |
| 1998 | 24.26 Million CNY | -10.06% |
| 1997 | 49.78 Million CNY | -22.25% |
| 1996 | 64.03 Million CNY | -16.84% |
| 1995 | 77 Million CNY | -15.23% |
| 1994 | 90.84 Million CNY | 0.0% |
| 1992 | 75.58 Million CNY | -0.68% |
| 1991 | 76.09 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 875.13 Million CNY | 123.61% |
| 2024 Q2 | 830.32 Million CNY | -15.6% |
| 2024 Q3 | 716.47 Million CNY | -13.71% |
| 2023 Q3 | 671.28 Million CNY | -10.15% |
| 2023 Q1 | 795.52 Million CNY | 65.35% |
| 2023 FY | - CNY | 12.11% |
| 2023 Q2 | 747.13 Million CNY | -6.08% |
| 2023 Q4 | 619.74 Million CNY | -7.68% |
| 2022 Q1 | 805.63 Million CNY | 96.3% |
| 2022 Q3 | 659.55 Million CNY | -2.79% |
| 2022 Q4 | 481.11 Million CNY | -27.05% |
| 2022 Q2 | 678.51 Million CNY | -15.78% |
| 2022 FY | - CNY | 14.78% |
| 2021 Q1 | 780.53 Million CNY | 94.84% |
| 2021 Q2 | 628.27 Million CNY | -19.51% |
| 2021 Q3 | 590.63 Million CNY | -5.99% |
| 2021 Q4 | 410.39 Million CNY | -30.52% |
| 2021 FY | - CNY | -4.03% |
| 2020 Q3 | 590.22 Million CNY | -42.37% |
| 2020 FY | - CNY | 36.73% |
| 2020 Q1 | 565.56 Million CNY | 69.74% |
| 2020 Q2 | 1.02 Billion CNY | 81.09% |
| 2020 Q4 | 400.61 Million CNY | -32.13% |
| 2019 Q1 | 528.13 Million CNY | 212.31% |
| 2019 FY | - CNY | 18.38% |
| 2019 Q2 | 489.01 Million CNY | -7.41% |
| 2019 Q3 | 430.24 Million CNY | -12.02% |
| 2019 Q4 | 333.19 Million CNY | -22.56% |
| 2018 Q1 | 383.63 Million CNY | -91.69% |
| 2018 Q4 | 169.1 Million CNY | -63.52% |
| 2018 Q3 | 463.57 Million CNY | 5.75% |
| 2018 FY | - CNY | -69.26% |
| 2018 Q2 | 438.38 Million CNY | 14.27% |
| 2017 Q4 | 4.61 Billion CNY | 1303.26% |
| 2017 Q2 | 380.79 Million CNY | 15.95% |
| 2017 Q3 | 329 Million CNY | -13.6% |
| 2017 Q1 | 328.39 Million CNY | 38.86% |
| 2017 FY | - CNY | 297.56% |
| 2016 Q4 | 236.49 Million CNY | -14.56% |
| 2016 FY | - CNY | 19.43% |
| 2016 Q3 | 276.8 Million CNY | -22.24% |
| 2016 Q2 | 355.96 Million CNY | 38.83% |
| 2016 Q1 | 256.4 Million CNY | -8.48% |
| 2015 Q2 | 272.59 Million CNY | 18.53% |
| 2015 Q4 | 280.17 Million CNY | 31.88% |
| 2015 Q3 | 212.45 Million CNY | -22.06% |
| 2015 Q1 | 229.97 Million CNY | 71.95% |
| 2015 FY | - CNY | 27.21% |
| 2014 FY | - CNY | 15.96% |
| 2014 Q4 | 133.74 Million CNY | -28.57% |
| 2014 Q3 | 187.23 Million CNY | -16.17% |
| 2014 Q2 | 223.35 Million CNY | 16.56% |
| 2014 Q1 | 191.62 Million CNY | -6.43% |
| 2013 Q4 | 204.78 Million CNY | 35.83% |
| 2013 Q1 | 163.93 Million CNY | -4.89% |
| 2013 Q3 | 150.77 Million CNY | -16.0% |
| 2013 FY | - CNY | 12.37% |
| 2013 Q2 | 179.48 Million CNY | 9.49% |
| 2012 Q3 | 143.78 Million CNY | -21.74% |
| 2012 Q1 | 135.21 Million CNY | -9.84% |
| 2012 FY | - CNY | 13.11% |
| 2012 Q2 | 183.71 Million CNY | 35.87% |
| 2012 Q4 | 172.36 Million CNY | 19.88% |
| 2011 FY | - CNY | 0.77% |
| 2011 Q1 | 150.24 Million CNY | 17.33% |
| 2011 Q2 | 146.93 Million CNY | -2.2% |
| 2011 Q3 | 112.18 Million CNY | -23.65% |
| 2011 Q4 | 149.96 Million CNY | 33.68% |
| 2010 Q3 | 108.42 Million CNY | -32.13% |
| 2010 FY | - CNY | 2.61% |
| 2010 Q1 | 152.51 Million CNY | -23.49% |
| 2010 Q2 | 159.75 Million CNY | 4.75% |
| 2010 Q4 | 128.05 Million CNY | 18.1% |
| 2009 Q4 | 199.35 Million CNY | 28.6% |
| 2009 FY | - CNY | 12.63% |
| 2009 Q3 | 155.01 Million CNY | -19.15% |
| 2009 Q2 | 191.73 Million CNY | 1216.65% |
| 2009 Q1 | 14.56 Million CNY | 117.82% |
| 2008 Q3 | 147.95 Million CNY | 16.81% |
| 2008 Q2 | 126.66 Million CNY | -18.2% |
| 2008 Q1 | 154.85 Million CNY | -64.63% |
| 2008 FY | - CNY | -14.73% |
| 2008 Q4 | -81.72 Million CNY | -155.24% |
| 2007 Q1 | 45.21 Million CNY | -67.64% |
| 2007 Q4 | 437.75 Million CNY | 4361.5% |
| 2007 Q3 | -10.27 Million CNY | -104.48% |
| 2007 Q2 | 229.3 Million CNY | 407.18% |
| 2007 FY | - CNY | 108.74% |
| 2006 Q4 | 139.7 Million CNY | 133.24% |
| 2006 Q3 | 59.9 Million CNY | -31.03% |
| 2006 Q2 | 86.84 Million CNY | 54.78% |
| 2006 Q1 | 56.1 Million CNY | -14.18% |
| 2006 FY | - CNY | 30.88% |
| 2005 FY | - CNY | 2.33% |
| 2005 Q4 | 65.37 Million CNY | 55.15% |
| 2005 Q3 | 42.13 Million CNY | -41.88% |
| 2005 Q2 | 72.5 Million CNY | 5.99% |
| 2005 Q1 | 68.4 Million CNY | -24.65% |
| 2004 Q4 | 90.78 Million CNY | 129.91% |
| 2004 FY | - CNY | -3.73% |
| 2004 Q1 | 61.41 Million CNY | -39.38% |
| 2004 Q2 | 83.79 Million CNY | 36.45% |
| 2004 Q3 | 39.48 Million CNY | -52.88% |
| 2003 Q3 | 21.65 Million CNY | -75.06% |
| 2003 Q4 | 101.32 Million CNY | 367.85% |
| 2003 FY | - CNY | 23.12% |
| 2003 Q1 | 53.64 Million CNY | 143.12% |
| 2003 Q2 | 86.81 Million CNY | 61.85% |
| 2002 Q3 | 30.24 Million CNY | -37.81% |
| 2002 Q2 | 48.64 Million CNY | 53.2% |
| 2002 FY | - CNY | 6.27% |
| 2002 Q1 | 31.75 Million CNY | 0.0% |
| 2002 Q4 | 22.06 Million CNY | -27.06% |
| 2001 FY | - CNY | 62.21% |
| 2000 FY | - CNY | 182.17% |
| 1999 FY | - CNY | -6.3% |
| 1998 FY | - CNY | -10.06% |
| 1997 FY | - CNY | -22.25% |
| 1996 FY | - CNY | -16.84% |
| 1995 FY | - CNY | -15.23% |
| 1994 FY | - CNY | 0.0% |
| 1992 FY | - CNY | -0.68% |
| 1991 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -2110.822% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | -12.085% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 2667.23% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -2821.911% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 6719.833% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -2927.751% |
| Essex Bio-Technology Limited | 418.37 Million HKD | -694.756% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -4238.961% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 12806.164% |
| SSY Group Limited | 2.11 Billion HKD | -57.247% |
| JBM (Healthcare) Limited | 204.39 Million HKD | -1526.829% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | -673.416% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 78.452% |